Table 1.
Baseline patient characteristics by prostate cancer status from biopsy result
| Prostate Cancer | Prostate Cancer Grade | |||||
|---|---|---|---|---|---|---|
| No PC | PC | p | Low-grade PC (Gleason 6) |
High-grade PC (Gleason 7–10) |
p | |
| No. Patients | 496 (51%) | 483 (49%) | – | 246 (51%) | 237 (49%) | – |
| Age, mean ± SD | 62.3 ± 6.1 | 62.5 ± 6.4 | 0.52* | 62.1 ± 6.3 | 63.0 ± 6.5 | 0.13* |
| Race | 0.001† | 0.07† | ||||
| Non-black | 244 (49%) | 172 (36%) | 78 (32%) | 94 (40%) | ||
| Black | 252 (51%) | 311 (64%) | 168 (68%) | 143 (60%) | ||
| PSA (ng/ml), median (IQR) | 5.5 (4.3, 7.2) | 6.4 (4.9, 9.4) | <0.001 ‡ | 5.8 (4.6, 7.6) | 7.4 (5.3, 12.9) | <0.001‡ |
| DRE | 0.007† | <0.001† | ||||
| Normal | 396 (80%) | 351 (72%) | 205 (83%) | 145 (61%) | ||
| Abnormal | 100 (20%) | 133 (28%) | 41 (17%) | 92 (39%) | ||
| TRUS volume (cc), median (IQR) | 49 (35, 68) | 34 (26, 50) | <0.001 ‡ | 37 (26, 54) | 31 (25, 44) | 0.002‡ |
| Gleason Score | – | – | ||||
| 6 | 0 | 246 51%) | 246 (100%) | 0 | ||
| 3+4 | 0 | 130 (27%) | 0 | 130 (55%) | ||
| 4+3 | 0 | 56 (12%) | 0 | 56 (24%) | ||
| 8−10 | 0 | 51 (10%) | 0 | 51 (22%) | ||
| Family history of PC | 0.64† | 0.45† | ||||
| No | 260 (52%) | 248 (51%) | 124 (50%) | 124 (52%) | ||
| Yes | 96 (19%) | 105 (22%) | 50 (20%) | 55 (23%) | ||
| Unknown | 140 (28%) | 130 (27%) | 72 (29%) | 58 (25%) | ||
| BMI (kg/m2), mean ± SD | 29.7 ± 5.1 | 29.8 ± 5.8 | 0.81* | 29.4 ± 5.8 | 30.3 ± 5.7 | 0.09* |
| % Body Fat, mean ± SD | 28.6 ± 6.0 | 28.3 ± 6.7 | 0.49* | 27.4 ± 6.9 | 29.3 ± 6.4 | 0.002* |
| Waist Circumference (cm), mean ± SD | 105. 9 ± 14.1 | 104.7 ± 14.7 | 0.18* | 103.0 ± 14.2 | 106.5 ± 15.0 | 0.010* |
Table cells are n (%) unless otherwise specified
PC = prostate cancer; SD = standard deviation, IQR = interquartile range, BMI = body mass index, DRE = previous digital rectal exam, PSA = prostate-specific antigen, TRUS = transrectal prostate volume
p-value calculated using *t-test, †chi-squared test, or ‡rank sum test